Trevena Enrolls First Patient For ACTIV-4 Host Tissue Study Of Its Covid Drug

(RTTNews) - Trevena, Inc. (TRVN) on Monday said first patient has been enrolled in the ACTIV-4 Host Tissue study of the company's investigational drug TRV027, for the treatment of Covid-19.

The ACTIV-4 Host Tissue (Accelerating COVID-19 Therapeutic Interventions and Vaccines) study, funded by NIH, is part of an initiative by NIH to develop a coordinated research strategy for prioritizing and speeding development of the most promising treatments and vaccines.

The study with four trial arms are testing investigational agents for the treatment of Covid-19 by enrolling about 1,600 patients at more than 50 sites in the U.S.

TRV027, as part of the initial trial launch, will be dosed in nearly 300 patients during the study led by Vanderbilt University Medical Center (VUMC).

TRV027 is currently being investigated by Trevena in acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.